{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chang YC"],"funding":["Ministry of Science and Technology, Taiwan"],"pagination":["e15298"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8988202"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(4)"],"pubmed_abstract":["The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC<sub>50</sub> in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2-transgenic mice, accompanied by a significant prevention of virus-associat"],"journal":["EMBO molecular medicine"],"pubmed_title":["A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant."],"pmcid":["PMC8988202"],"funding_grant_id":["MOST 109‐2124‐M‐002‐012","MOST‐110‐2740‐B‐002‐006","MOST 110‐0210‐01‐22‐02","MOST 109‐0210‐01‐18‐02","MOST109‐2327‐B‐002‐009"],"pubmed_authors":["Chang JY","Hsu SC","Fang JT","Tsai YM","Chou YL","Chen YF","Chang FY","Chao TL","Kao HC","Chang TY","Chang SY","Yang CF","Lu HY","Chang YC","Chou HW","Weng RS","Chin YF","Tu QW","Huang KY","Yang CC","Liu PC","Lee TY","Ieong SM","Yang PC"],"additional_accession":[]},"is_claimable":false,"name":"A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant.","description":"The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC<sub>50</sub> in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2-transgenic mice, accompanied by a significant prevention of virus-associat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-10T00:56:51.441Z","creation":"2025-04-07T01:53:12.306Z"},"accession":"S-EPMC8988202","cross_references":{"pubmed":["35138028"],"doi":["10.15252/emmm.202115298"]}}